High estrogen receptor alpha activation confers resistance to estrogen deprivation and is required for therapeutic response to estrogen in breast cancer

Estrogen receptor alpha (ER)-positive breast cancer is commonly treated with endocrine therapies, including anti-estrogens that bind and inhibit ER activity, and aromatase inhibitors that suppress estrogen biosynthesis to inhibit estrogen-dependent ER activity. Paradoxically, treatment with estrogen...

Descripción completa

Detalles Bibliográficos
Autores principales: Traphagen, Nicole A., Hosford, Sarah R., Jiang, Amanda, Marotti, Jonathan D., Brauer, Brooke L., Demidenko, Eugene, Miller, Todd W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8122072/
https://www.ncbi.nlm.nih.gov/pubmed/33875787
http://dx.doi.org/10.1038/s41388-021-01782-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8122072/
https://www.ncbi.nlm.nih.gov/pubmed/33875787
http://dx.doi.org/10.1038/s41388-021-01782-w

Ejemplares similares